Gregory Harriman, MD
Dr. Gregory Harriman is a venture partner at BioAdvance. BioAdvance provides funding to startup life sciences companies in the Mid-Atlantic region through investments in therapeutics, devices, diagnostics and platform technologies focused on human health. Dr. Harriman is an accomplished physician, scientist and biomedical executive with more than 25 years of experience with increasing responsibilities in academic medicine and the biopharmaceutical industry. He has held leadership positions in both small and large biopharmaceutical companies, having global responsibilities in research and development of pharmaceuticals, biologics, medical devices and cell therapies. He has led successful regulatory submissions in the US (both NDAs and BLAs), EU (MAAs) and Japan (NDAs) and has presented to FDA Advisory Committees and the EMEA. Dr. Harriman attended the University of California, Berkeley, as an undergraduate and received his MD degree at the University of California, San Diego. He trained in internal medicine at Barnes Hospital and completed a fellowship in infectious diseases at the NIH. He is board-certified in internal medicine, infectious diseases and clinical & laboratory immunology. He had a successful academic career at the NIH and Baylor College of Medicine, publishing more than 40 scientific papers, obtaining R01 and U01 grant funding from the NIH as well as private foundation funding, and conducting innovative research in immunology, vaccines and immune-mediated diseases. He is a fellow of the American College of Physicians and is a member of several other professional medical organizations.
Michael J. Morin, PhD
Chairman of the Board
Mike Morin, PhD, Immunome President, Chief Executive Officer and Chairman of the Board, has had a productive career in cancer research, with a long-standing commitment to improving patient care. As Vice President in Pfizer Global R&D, he led Antibacterials, Immunology and Cancer drug discovery in Groton, CT. During his extensive Pfizer career, Mike had oversight for the discovery of approximately 40 clinical candidates, many of which are progressing in active development. Most notable among those activities was his direct leadership in the discovery through Phase 2 proof-of-concept for erlotinib (TarcevaTM), a small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase (a blockbuster drug marketed by Roche and Astellas). Additional candidates from his teams, both monoclonal antibodies and small molecules, have also achieved full development status and are moving through late-stage clinical trials and NDA filings. Since 2008, Mike worked as an advisor and as a C-level interim leader of venture-backed biotechnology companies, including Supportive Therapeutics (CEO) and Onkaido (CSO). Mike remains a committed supporter of academic cancer programs at the local and national levels, and he continues to contribute to the peer-review process within the cancer research community. This includes many years of service as co-chair of the NCI Experimental Therapeutics (NExT) review panel, chair of the Drug Discovery Initiative of the Children’s Tumor Foundation, and the Scientific Advisory Boards of the Ontario Institute of Cancer Research and of the Terri Brodeur Breast Cancer Foundation. Mike also serves as an executive advisor for the sciences and new ventures at UMass Lowell, where he is also an adjunct professor in the Kennedy College of Sciences. Mike received his baccalaureate in Biological Sciences from UMass Lowell and his PhD in Cancer Pharmacology from SUNY Buffalo (Roswell Park Graduate Division). He was an NIH postdoctoral fellow with Professor Alan Sartorelli at the Yale Comprehensive Cancer Center.
Wistar Morris, III
Wistar Morris, III is Senior Investment Consultant to Pennsylvania Trust. In April 2011, he retired from Boenning & Scattergood, an Investment Securities firm, where he served as a Director and Investment Advisor for 20 years. Previously, Mr. Morris founded the Morris Investment Management Company and held the roles of President and Chairman. Mr. Morris was also Executive Vice President with the investment management firm Hopper Soliday & Co. Mr. Morris has been on the boards of 20 public and private companies. In the non-profit world, he currently serves as emeritus trustee to The Academy of Natural Science, Lankenau Medical Center, Lankenau Institute of Medical Research and the Mount Desert Island Biological Laboratory. He is the Founder and CEO of The Cotswold Foundation and is the author of Adventures in Investing which describes his career in the investment business. Mr. Morris received a BS degree in Chemistry from Cornell University, an MBA from the Harvard Business School, and holds the CFA designation from the CFA Institute.
Michael Rapp has more than 26 years of experience in the financial industry and is the co-managing partner of Broadband Capital Partners, LLC, a middle-market private equity sponsor focused on growth companies and industry consolidations. Prior to Broadband Capital Partners, Mr. Rapp was the chairman of Broadband Capital Management LLC, an investment and merchant bank he co-founded in 2000. Mr. Rapp led the 2014 recapitalization of Zynerba Pharmaceuticals (Nasdaq: ZYNE), a life sciences company dedicated to developing next-generation synthetic cannabinoid therapeutics, and was instrumental in the identification and hiring of new management, culminating with the company’s August 2015 IPO led by Jefferies and Piper Jaffray. Mr. Rapp also has extensive experience with public and private growth equity investments, including ExamWorks (Nasdaq: EXAM), One Group Hospitality (Nasdaq: STKS), vroom.com and Montrose Environmental Group. Mr. Rapp is currently chairman of the board of directors of Committed Capital Acquisition Corporation II (OTCQB: CCAQ) and a member of the board of directors of Omtool, Ltd. Mr. Rapp received his BA degree in psychology from the University of Michigan-Ann Arbor in 1989.
Mr. Waggenheim has more than 24 years of experience in the financial industry and is the co-managing partner of Broadband Capital Partners, LLC, a middle-market private equity sponsor focused on growth companies and industry consolidations. Prior to Broadband Capital Partners, he was the vice-chairman of Broadband Capital Management LLC, an investment and merchant bank he co-founded in 2000. Mr. Wagenheim has extensive experience with public and private growth equity investments, including Zynerba Pharmaceuticals (Nasdaq: ZYNE), ExamWorks (Nasdaq: EXAM), One Group Hospitality (Nasdaq: STKS), vroom.com and Montrose Environmental Group. In connection with Zynerba’s recapitalization, Mr. Wagenheim was named President and a Director of the company, serving as a director until the company’s initial public offering in August 2015 led by Jefferies and Piper Jaffray. Mr. Wagenheim also serves as a director of Committed Capital Acquisition Corporation II (OTCQB: CCAQ). Mr. Wagenheim received his degree in Business Administration from the University of Miami.
Michael Widlitz, MD
Dr. Michael Widlitz, MD, has more than 30 years of experience in the health care industry including clinical practice and 20-plus years in the pharmaceutical industry with expertise in clinical development and medical affairs. He currently serves as a consultant to the pharmaceutical, biotechnology, and medical device industries. Prior to his consulting activities, Dr. Widlitz served as Vice President, US Medical for the Specialty Markets at Pfizer, leading the medical teams responsible for the Oncology, HIV/Anti-infective, Ophthalmology, Endocrine Care and Diversified Product Portfolios. His areas of responsibility included strategy development (clinical development through commercial products); clinical trial management; clinical data interpretations; and medical communications relative to key products, such as Sutent®, Macugen® & Eraxis™. Previously at Pfizer, Dr. Widlitz served as Vice President and Group Leader in Urology, Respiratory, Arthritis and Women’s Health franchises supporting key global product launches and leading Medical Affairs for products including Viagra®, Celebrex® and Zyrtec®. He also led the medical teams that provided support to Pfizer’s New Product Development Group. Dr. Widlitz serves on the Melanoma Advisory Board at the Wistar Institute and as a Business Advisor/Selection Team member to the University City Science Center QED Program. He is also an active life science angel investor through the Mid-Atlantic Angel Group, leading many of its Life Science sector due diligence activities. Dr. Widlitz earned a BA degree with distinction from the University of Michigan. He received his MD from George Washington University School of Medicine and completed a residency in otolaryngology at Albert Einstein College of Medicine. He is Board Certified by the American Board of Otolaryngology and Head and Neck Surgery.